Published in J Clin Endocrinol Metab on November 16, 2011
β-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes (2014) 0.86
GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin Sci (Lond) (2014) 0.83
Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J Diabetes (2014) 0.78
Enteroendocrine secretion after Roux-en-Y gastric bypass: is it important? Neurogastroenterol Motil (2013) 0.77
Mechanism of action of DPP-4 inhibitors--new insights. J Clin Endocrinol Metab (2012) 0.77
Correlation of Glypican-4 Level with Basal Active Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes Mellitus. Endocrinol Metab (Seoul) (2016) 0.76
Glucose-Dependent Insulinotropic Peptide Level Is Associated with the Development of Type 2 Diabetes Mellitus. Endocrinol Metab (Seoul) (2016) 0.76
Defective Glucagon-Like Peptide 1 Secretion in Prediabetes and Type 2 Diabetes Is Influenced by Weight and Sex. Chicken, Egg, or None of the Above? Diabetes (2015) 0.75
Exocrine and Endocrine Interactions in Cystic Fibrosis: A Potential Key to Understanding Insulin Secretion in Health and Disease? Diabetes (2017) 0.75
Predicting diabetes using measures of β-cell function. Diabetes (2012) 0.75
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 15.76
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA (2003) 13.79
Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes (1992) 4.47
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1993) 3.63
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab (2001) 3.09
A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes (2003) 2.77
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia (2010) 2.40
Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes (1995) 2.30
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes (2007) 2.19
Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia (2007) 2.16
Minireview: the glucagon-like peptides. Endocrinology (2001) 2.15
Minimal model estimation of glucose absorption and insulin sensitivity from oral test: validation with a tracer method. Am J Physiol Endocrinol Metab (2004) 2.04
Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes (2006) 2.02
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia (2010) 1.98
Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies. Diabetologia (2007) 1.67
Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes (2010) 1.40
Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology (2006) 1.36
Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia (2008) 1.35
Systemic and regional free fatty acid metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab (2001) 1.33
Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab (2003) 1.26
Effects of changing diagnostic criteria on the risk of developing diabetes. Diabetes Care (1998) 1.25
Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab (2009) 1.22
Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes. Diabetes Care (2008) 1.20
Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia (2000) 1.19
The gastrointestinal tract and glucose tolerance. Curr Opin Clin Nutr Metab Care (2004) 1.07
Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance. Am J Physiol Endocrinol Metab (2006) 1.05
Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes (2000) 1.05
Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab (2010) 1.04
Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. Eur J Endocrinol (1997) 0.96
Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions. Diabet Med (2010) 0.92
Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes (2001) 0.85
Mechanism of postprandial hyperglycaemia in diabetes mellitus. Eur J Gastroenterol Hepatol (1995) 0.80
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet (2007) 19.04
Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes (2003) 16.62
Functional gastroduodenal disorders. Gastroenterology (2006) 8.51
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 6.76
Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med (2007) 6.00
In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol (2009) 5.24
Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes (2008) 5.23
Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes (2004) 4.81
Chronic constipation. N Engl J Med (2003) 4.58
The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol (2011) 3.92
Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis (2007) 3.83
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol (2007) 3.65
A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology (2013) 3.56
Meal simulation model of the glucose-insulin system. IEEE Trans Biomed Eng (2007) 3.54
Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology (2008) 3.52
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol (2010) 3.48
Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes (2012) 3.40
Impact of aerobic exercise training on age-related changes in insulin sensitivity and muscle oxidative capacity. Diabetes (2003) 3.23
Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol (2007) 3.14
High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes. Diabetes (2007) 2.96
Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A (2006) 2.88
Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology (2006) 2.87
A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol (2011) 2.81
The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology (2002) 2.78
Prevalence and burden of fecal incontinence: a population-based study in women. Gastroenterology (2005) 2.64
Independent influences of body mass and gastric volumes on satiation in humans. Gastroenterology (2004) 2.63
Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol (2009) 2.55
Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes (2003) 2.53
Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology (2004) 2.48
Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol (2003) 2.47
Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care (2006) 2.46
Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol (2007) 2.44
Endoscopic skipping of the distal terminal ileum in Crohn's disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol (2012) 2.41
Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol (2006) 2.38
Impact of lymph node staging on therapy of esophageal carcinoma. Gastroenterology (2003) 2.35
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.32
Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: preliminary studies in Padova and Montpellier. J Diabetes Sci Technol (2009) 2.31
Glucose concentration can be predicted ahead in time from continuous glucose monitoring sensor time-series. IEEE Trans Biomed Eng (2007) 2.31
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology (2007) 2.30
Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc (2008) 2.30
A study of candidate genotypes associated with dyspepsia in a U.S. community. Am J Gastroenterol (2006) 2.30
Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. Diabetes Care (2013) 2.26
Evaluating the efficacy of closed-loop glucose regulation via control-variability grid analysis. J Diabetes Sci Technol (2008) 2.24
β-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care (2012) 2.20
Effects of age and sex on postprandial glucose metabolism: differences in glucose turnover, insulin secretion, insulin action, and hepatic insulin extraction. Diabetes (2006) 2.20
Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology (2007) 2.14
Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol (2012) 2.13
GIM, simulation software of meal glucose-insulin model. J Diabetes Sci Technol (2007) 2.11
Diabetes: Models, Signals, and Control. IEEE Rev Biomed Eng (2009) 2.11
The impact of planned care and a diabetes electronic management system on community-based diabetes care: the Mayo Health System Diabetes Translation Project. Diabetes Care (2002) 2.07
Mucosal atrophy in celiac disease: extent of involvement, correlation with clinical presentation, and response to treatment. Clin Gastroenterol Hepatol (2007) 2.07
Minimal model estimation of glucose absorption and insulin sensitivity from oral test: validation with a tracer method. Am J Physiol Endocrinol Metab (2004) 2.04
Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol (2008) 2.04
Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes (2006) 2.02
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab (2007) 2.02
Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis (2007) 1.97
The epidemiology of microscopic colitis: a population based study in Olmsted County, Minnesota. Gut (2006) 1.97
Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab (2009) 1.94
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 1.94
Phenotypic identification and classification of functional defecatory disorders using high-resolution anorectal manometry. Gastroenterology (2012) 1.93
Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2008) 1.93
Modeling chronic glycemic exposure variables as correlates and predictors of microvascular complications of diabetes. Diabetes Care (2006) 1.93
Use of a novel triple-tracer approach to assess postprandial glucose metabolism. Am J Physiol Endocrinol Metab (2003) 1.92
Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes (2013) 1.90
Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol (2008) 1.90
Drawing a blank in functional dyspepsia? Gastroenterology (2006) 1.89
The oral glucose minimal model: estimation of insulin sensitivity from a meal test. IEEE Trans Biomed Eng (2002) 1.88
Diarrhea-predominant irritable bowel syndrome is associated with diverticular disease: a population-based study. Am J Gastroenterol (2009) 1.88
Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology (2008) 1.87
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol (2009) 1.87
Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol (2003) 1.86
Age-related changes in the pancreas identified by EUS: a prospective evaluation. Gastrointest Endosc (2005) 1.86
Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol (2004) 1.86
Celiac disease serology in irritable bowel syndrome and dyspepsia: a population-based case-control study. Mayo Clin Proc (2004) 1.85
Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol (2005) 1.84
Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve (2010) 1.82
Obstetric trauma, pelvic floor injury and fecal incontinence: a population-based case-control study. Am J Gastroenterol (2012) 1.82